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ABSTRACT – Purpose. A few studies have shown that normothermic hepatic ischemia-reperfusion (IR) injury
may affect the mRNA and/or protein levels of canalicular transporters P-glycoprotein (P-gp) and multidrug
resistance-associated protein 2 (Mrp2). However, the effects of the injury on the functions of these canalicular
transporters with respect to the biliary excretion of drugs remain largely unknown. Therefore, the purpose of this
study was to investigate the effects of warm hepatic IR on the hepatobiliary disposition of rhodamine 123 (RH123), a P-gp substrate, and its glucuronidated metabolite (RH-Glu), an Mrp2 substrate, in rats. Methods.
Twenty four or 72 h following a 60-min partial ischemia or sham operation in rats, livers were isolated and
perfused ex vivo with a constant concentration (~100 ng/mL) of RH-123. The concentration of RH-123 and its
glucuronidated (RH-Glu) and deacylated (RH-110) metabolites were determined in the outlet perfusate, bile,
and the liver tissue using HPLC, and relevant pharmacokinetic parameters were estimated. Results. Twentyfour-h IR caused a significant reduction in the hepatic extraction ratio of RH-123 (IR: 0.857 ± 0.078; Sham:
0.980 ± 0.017) and the biliary recovery of the parent drug and RH-Glu by 43% and 44%, respectively. The
reductions in the biliary recovery were associated with significant reductions in the apparent biliary clearance of
RH-123 and RH-Glu. Mass balance data showed that the formation of the glucuronidated or deacylated
metabolite was not significantly affected by the 24-h IR injury. In contrast to the 24-h IR, the injury did not have
any effect on the hepatobiliary disposition of RH-123 or its metabolites following 72 h of reperfusion.
Conclusions. It is concluded that the pharmacokinetics of drugs that are subject to biliary excretion by the
canalicular P-gp and Mrp2 transporters may be altered shortly after hepatic IR injury.
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
_______________________________________________________________________
the canalicular transporters P-glycoprotein (P-gp)
and multidrug resistance-associated protein 2
(Mrp2) may be altered by warm hepatic IR injury.
However, the effects of the injury on the functions
of these canalicular transporters with respect to the
biliary excretion of drugs remain largely unknown.
This is important because the functional changes in
the activity of proteins do not always correlate with
the changes in their mRNA or protein levels (11).
Therefore, it is necessary to investigate the changes
in the activity of liver transporters after hepatic IR
injury.
_________________________________________

INTRODUCTION
Warm hepatic ischemia-reperfusion (IR) injury is a
serious complication of many clinical situations,
such as hepatic resection surgery, hemorrhagic and
septic shock, and liver transplantation (1-3).
Numerous factors, such as the release of reactive
oxygen species (ROS) and proinflammatory
cytokines, have been reported to be involved in the
pathophysiology of hepatic IR injury (4). Previous
studies have shown that the inflammatory processes
resulting in the release of cytokines may alter the
expression of hepatic transporters (5, 6). Therefore,
it is likely that the expression and function of these
transporters are altered after the liver IR injury.
Indeed, the limited data available in the literature
(7-10) suggest that the mRNA and protein levels of
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measurement of alanine aminotransferase (ALT)
were purchased from Teco Diagnostics (Anaheim,
CA, USA). All other reagents were of analytical
grade and obtained from commercial sources.

The cationic dye rhodamine 123 (RH-123) is a
P-gp substrate, which has been used extensively as
a marker of P-gp activity in vitro in cells, ex vivo in
isolated organs, and in vivo in whole animals. We
have recently (12) characterized the hepatobiliary
disposition of RH-123 in an isolated perfused liver
(IPRL) model and showed that the biliary excretion
of the dye is reduced after pharmacological
inhibition of P-gp activity (13). Additionally, it was
shown that the biliary clearance of the
glucuronidated metabolite of the dye (RH-Glu) is
sensitive to the modulation of Mrp2 activity (13).
Based on these observations, it was suggested that
RH-123 may serve as a dual marker for the
functions of both P-gp and Mrp2 in the IPRL model
via simultaneous monitoring of the biliary
clearances of the parent drug and the generated
glucuronide
metabolite,
respectively
(13).
Therefore, we selected RH-123 as a marker for our
functional studies in the present study.
Previous studies have shown that the hepatic IR
injury is associated with injury to remote organs,
such as the lungs (14, 15) and kidneys (16, 17).
This may complicate the delineation of the effects
of hepatic IR on the canalicular efflux transporters
after in vivo administration of RH-123. To avoid
these confounding effects, we chose to determine
the hepatobiliary disposition of RH-123 and its
metabolites ex vivo in livers isolated from the
animals that underwent in vivo IR injury. Earlier
reports suggested a significant downregulation of
mRNA (10) and protein (8) levels of Mrp2 in the
liver as a result of hepatic IR. However, the mRNA
(Mdr1b) (10) and protein (7) levels of P-gp were
upregulated after the injury. Therefore, we
hypothesized that whereas hepatic IR injury would
increase the biliary transport of RH-123, the biliary
excretion of its glucuronidated metabolite would be
reduced by the injury.

Animals
The procedures involving animals were approved
by the Texas Tech University Health Sciences
Center Animal Care and Use Committee and were
consistent with the guidelines set by the National
Institutes of Health (NIH publication #85-23,
revised 1985).
Adult (225-275 g), male Sprague-Dawley rats
were purchased from Charles River Laboratories,
Inc. (Wilmington, MA, USA). All animals were
maintained on a 12-h light/dark cycle with free
access to food and water before the experiments.
Experimental groups and partial hepatic
ischemia-reperfusion surgery
A total of 28 rats underwent 1 h of partial (70%)
ischemia (IR) or sham operation (Sham), followed
by 24 or 72 h of in vivo reperfusion, resulting in
four groups of Sham-24 (n=8), IR-24 (n=8), Sham72 (n=6), and IR-72 (n=6).
The surgical procedures for IR were similar to
those described before (18, 19). Briefly, after an
overnight fast, animals were anesthetized by an
intramuscular administration of ketamine: xylazine
(80:10 mg/kg body weight). Partial ischemia was
then induced by clamping those branches of the
portal vein, hepatic artery, and bile duct that supply
the left and median lobes of the liver, leaving the
perfusion to the right and caudate lobes
uninterrupted. During ischemia, temperature of the
rat was closely monitored and maintained at 37º C
using a combination of a heating lamp and a heating
plate. After 60 min of partial ischemia, the clamp
was removed to allow reperfusion. Subsequently, 5
mL of sterile saline (37o C) was added to the
peritoneal cavity to compensate for any volume loss
during the surgery before closure of the abdomen.
Sham-operated animals underwent the same
surgical procedure without clamping.

MATERIAL AND METHODS
Chemicals and reagents
RH-123 was obtained from MP Biomedicals
(Solon, OH, USA). Rhodamine-110 (RH-110) and
β-glucuronidase (TYPE -LII) were purchased from
Sigma Chemicals Co. (St. Louis, MO, USA). For
anesthesia, ketamine and xylazine solutions were
purchased from Lloyd Laboratories (Shenandoah,
IA, USA) and Fort Dodge Animal Health (Fort
Dodge, IA, USA), respectively. Kits for

Isolation and ex vivo perfusion of livers with RH123
After 24 or 72 h in vivo reperfusion, livers were
cannulated, harvested, and perfused ex vivo for 60
min by the method outlined by us in details earlier
(20, 21). The perfusion was conducted in a water-

319

J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(2) 318 - 328, 2012

jacketed glass perfusion system (Radnoti Glass
Technology Inc., Monrovia, CA) using KrebsHenseleit bicarbonate buffer that contained 4.75
mg/L sodium taurocholate and 1.2 g/L glucose.
Livers were perfused at a flow rate of 30 mL/min in
a single-pass manner with a constant concentration
(0.1 µg/mL) of RH-123. The perfusate was
continuously oxygenated with 95% oxygen and 5%
carbon dioxide mixture, and the inlet perfusion
pressure was monitored using a pressure transducer.
The viability of the liver was confirmed by
monitoring the macroscopic appearance of the liver,
relatively stable bile flow rates over the entire
period of perfusion (60 min), wet liver weight of <
4% of total body weight at the end of perfusion, low
transaminase (ALT) levels in the outlet perfusate
during the perfusion period (0 and 60 min), and low
and stable inlet pressure.

Perfusate and plasma concentrations of ALT
were measured by spectrophotometry using a
commercially available kit.

Sample collection
At the end of the 24 or 72 h of in vivo reperfusion
period, blood was collected from the abdominal
aorta into the heparinized syringes, and after
centrifugation, plasma was separated and stored for
the analysis of ALT.
For the liver perfusion experiments, inlet
perfusate samples were drawn at 20, 30, and 40 min
after starting the constant infusion of RH-123.
Additionally, outlet perfusate and bile samples were
collected at 10 min intervals during the 60 min
infusion of RH-123. At the end of the perfusion,
livers were blotted dry and stored for further
analysis. Perfusate, bile, and liver samples were
stored at -80o C for subsequent analysis of RH-123,
RH-110, and RH-Glu by high-performance liquid
chromatography (HPLC).

where Xout and Xin are the amount of RH-123
recovered in the perfusate from zero to 60 min and
the total dose of RH-123 administered during the
same period, respectively. Xout was estimated by
multiplying the perfusate AUC of RH-123 by the
perfusate flow (Q), which was 30 mL/min, and Xin
was estimated by multiplying the Cin by the Q and
duration of the perfusion (60 min). The timeaveraged hepatic extraction ratio (E) and hepatic
clearance (CLh) of RH-123 were then estimated
using the following equations:

Pharmacokinetic analysis
The areas under the perfusate concentration-time
curve from 0 to 60 min (AUC) for RH-123, RH110, and RH-Glu were calculated using linear
trapezoidal method. RH-123 inlet concentrations
(Cin) were calculated from the average of the three
inlet samples drawn at 20, 30, and 40 min of
perfusion. The time-averaged hepatic availability of
RH-123 during the 60-min perfusion period (F) was
estimated using the following equation:

F

Xout
Xin

(1)

(2)
E  1 F
CLh  Q  E (3)
Biliary excretion rates of RH-123 and RH-Glu at
any given time interval were determined by
dividing the total amount of the drug or metabolite
excreted into the bile during that interval by the
length of the collection interval. The apparent
biliary clearance (CLbile,app) of RH-123 or its
generated metabolite RH-Glu were estimated by
dividing the total amount of the drug or the
metabolite excreted into the bile during the 60 min
of perfusion by its respective perfusate AUC during
the same period. Because of continuous
accumulation and sequestration of RH-123 in the
liver tissue during the constant infusion of RH-123
in IPRLs despite pseudo-steady state perfusate
concentrations, the CLbile,app of RH-123 is expected
to increase with an increase in the length of
perfusion (12). Therefore, another parameter,

SAMPLE ANALYSIS
Liver samples were homogenized in deionized
water (1:9), and after an additional ten-fold dilution
were used in the assay. The concentrations of RH123 and RH-110 in the liver homogenates,
perfusate, and bile were analyzed by fluorescence
HPLC both before and after treatment with glucuronidase, as described by us before (12). The
concentrations of RH-Glu were then determined by
subtracting the RH-123 concentrations in the
unhydrolyzed samples from those in the
corresponding hydrolyzed samples.
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high CLh values close to the perfusion flow rate of
30 mL/min (Table 1).

termed biliary excretion index (BEI), was also
calculated for RH-123 as shown in the following
equation:

BEI (%) 

Dbile
100
Dliver

(4)

where Dbile and Dliver are the amounts of RH-123
recovered in the bile during the perfusion period
and that recovered in the liver at the end of
perfusion, respectively. This parameter is similar in
concept to the BEI estimated in sandwich-cultured
rat hepatocytes (22). In contrast to CLbile,app, which
normalizes the amount of RH-123 excreted in the
bile by the extent of drug exposure in the perfusate,
BEI normalizes the biliary excretion of the drug by
the extent of its liver accumulation. Therefore, it is
not expected to be dependent on the length of
constant infusion of the drug in IPRLs.

Figure 1. The plasma concentrations of alanine
aminotransferase (ALT) following 24 or 72 h of
reperfusion in rats subjected to 60 min of partial
ischemia (IR) or sham operation (Sham). The columns
and bars represent the mean and SD values, respectively.
*** p<0.001, significantly different from the respective
Sham group based on two-way ANOVA, followed by
Bonferroni’s post-hoc analysis.

STATISTICAL ANALYSIS
The effects of IR and time of reperfusion on
different kinetic parameters were tested using twoway ANOVA followed by Bonferroni’s post-hoc
analysis of the means. Also, two-way ANOVA with
repeated measures followed by Bonferroni’s posthoc was used to compare the biliary excretion rates
at different time points across the four treatment
groups. In all the cases, p<0.05 was considered
significant. All data are presented as mean ± SD.

However, the outlet concentrations (Figure 2A) and
AUC values (Table 1) for the IR-24 group were
much higher (p<0.001) than those of the Sham-24
group. In addition, the extraction ratio and CLh of
RH-123 were significantly (p<0.001) lower in this
group (Table 1). Whereas the outlet concentrations
and AUC values of the deacylated metabolite (RH110) were similar in all of the four groups (Figure
2B and Table 1), those of RH-Glu were
significantly (p<0.01) increased in the IR-24 group
(Figure 2C and Table 1).
The biliary excretion rate-time profiles (A) and
fraction of the dose recovered in the bile (B) are
depicted in Figures 3 and 4 for the parent drug RH123 and the formed RH-Glu metabolite,
respectively. The biliary excretion rates of RH-123
and RH-Glu in the IR-24 group were significantly
(p<0.05 or < 0.01) lower during some intervals,
when compared with the rates at the corresponding
times in the control group (Sham-24) (Figures 3A
and 4A). Likewise, the biliary recoveries of RH-123
and RH-Glu in the IR-24 rats were reduced
(p<0.05) by 43% (Figure 3B) and 44% (Figure 4B),
respectively. In contrast, both the biliary excretion
rates and recoveries of RH-123 and RH-Glu in the
IR-72 group were not different from those in the
Sham-72
group
(Figures
3
and
4).

RESULTS
The plasma concentrations of ALT, as a marker of
liver damage after IR, are shown in Figure 1.
Whereas the plasma concentrations of ALT in the
IR group were significantly (p<0.001) higher than
those in the Sham group 24 h after the in vivo
reperfusion, similar concentrations of ALT were
found in the IR and Sham groups at 72 h postreperfusion (Figure 1).
The outlet perfusate concentration-time profiles
and associated pharmacokinetic parameters of RH123 and its metabolites are depicted in Figure 2 and
Table 1, respectively. Except for the IR-24 group,
the
pseudo-steady-state
outlet
perfusate
concentrations of RH-123 in all different groups
were similarly low (3-5 ng/mL) (Fig 2A), resulting
in extensive extraction ratios of 0.972-0.980 and
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Table 1. Perfusate Pharmacokinetic Parameters of RH-123 and Its Main Metabolites RH-110 and RH-Glu in IPRL
Preparations
AUC (ng.min/mL)
RH-123
Treatment
RH-123
RH-110
RH-Glu
E
CLh (mL/min)
Sham-24
112 ± 95
328 ± 216
44.6 ± 37.5
0.980 ± 0.017
29.4 ± 0.5
IR-24
801 ± 445***
240 ± 50
89.6 ± 21.7**
0.857 ± 0.078***
25.7 ± 2.3***
Sham-72
117 ± 49
308 ± 39
57.2 ± 17.9
0.979 ± 0.009
29.4 ± 0.3
IR-72
160 ± 55
291 ± 16
37.5 ± 10.9
0.972 ± 0.009
29.1 ± 0.3
Livers were collected from rats subjected to 1 h of partial hepatic ischemia (IR) or sham operation (Sham), followed by
24 or 72 h of in vivo reperfusion and perfused ex vivo with a constant concentration (100 ng/mL) of RH-123 for 60
min.Data are presented as mean ± SD. ** p<0.01 and *** p<0.001, significantly different from the corresponding Sham
group (two-way ANOVA followed by Bonferroni’s post-hoc analysis).
hepatic ischemia (IR) or sham operation (Sham),
followed by 24 or 72 h of in vivo reperfusion. Mean
values are shown without SD bars for clarity.

Figure 3. The biliary excretion rate-time profiles (A) and
cumulative biliary excretion (B) of RH-123 in isolated
livers perfused with a constant inlet concentration of 100
ng/mL of RH-123 for 60 min. Livers were collected from
rats subjected to 1 h of partial hepatic ischemia (IR) or
sham operation (Sham), followed by 24 or 72 h of in vivo
reperfusion. The symbols or columns represent the mean
values and bars represent the SD values. * p<0.05 and **
p<0.01, significantly different from the respective Sham
group based on repeated measure (A) or regular (B) twoway ANOVA, followed by Bonferroni’s post-hoc
analysis.

Figure 2. The outlet perfusate concentration-time
profiles of RH-123 (A), RH-110 (B), and RH-Glu (C) in
isolated livers perfused with a constant inlet
concentration of 100 ng/mL of RH-123 for 60 min.
Livers were collected from rats subjected to 1 h of partial
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J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(2) 318 - 328, 2012

kinetic parameters, no differences were observed
between the IR-72 and Sham-72 groups in their
CLbile,app and BEI values (Figure 5).

Figure 4. The biliary excretion rate-time profiles (A) and
cumulative biliary excretion (B) of RH-Glu in isolated
livers perfused with a constant inlet concentration of 100
ng/mL of RH-123 for 60 min. Livers were collected from
rats subjected to 1 h of partial hepatic ischemia (IR) or
sham operation (Sham), followed by 24 or 72 h of in vivo
reperfusion. The symbols or columns represent the mean
values and bars represent the SD values. * p<0.05,
significantly different from the respective Sham group
based on repeated measure (A) or regular (B) two-way
ANOVA, followed by Bonferroni’s post-hoc analysis.

The apparent biliary clearance (A) and BEI (B)
of RH-123 and CLbile,app of RH-Glu (C) are
presented in Figure 5. The BEI values could not be
estimated for RH-Glu because, in agreement with a
previous report (12), no RH-Glu was detected in the
liver. Both CLbile,app (Figure 5A) and BEI (Figure
5B) values of RH-123 in the IR-24 group were
substantially lower than the corresponding values in
the Sham-24 group. However, the extent of
reduction in the CLbile,app value (92%, p<0.001) was
more than that observed in the BEI value (50%).
The CLbile,app value of RH-Glu was also reduced
(p<0.01) by 83% as a result of IR injury in the 24
h-reperfusion group (Figure 5C). Similar to other

Figure 5. The apparent biliary clearance (A) and biliary
excretion index (B) of RH-123 and apparent biliary
clearance of RH-Glu (C) in isolated livers perfused with
a constant inlet concentration of 100 ng/mL of RH-123
for 60 min. Livers were collected from rats subjected to 1
h of partial hepatic ischemia (IR) or sham operation
(Sham), followed by 24 or 72 h of in vivo reperfusion.
The columns and bars represent the mean and SD values,
respectively. ** p<0.01 and *** p<0.001, significantly
different from the respective Sham group based on twoway ANOVA, followed by Bonferroni’s post-hoc
analysis.
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isolated livers perfused with a constant inlet
concentration of 100 ng/mL of RH-123 for 60 min.
Livers were collected from rats subjected to 1 h of partial
hepatic ischemia (IR) or sham operation (Sham),
followed by 24 or 72 h of in vivo reperfusion. The
columns and bars represent the mean and SD values,
respectively.

The mass balance data for RH-123 (A), RH-Glu
(B), RH-110 (C), and total drug/metabolites (D) are
presented in Figure 6. The major moiety recovered
was the parent drug (Figure 3A), which was present
in the perfusate, bile, and the liver tissue, with the
highest recovery (26-35% of the dose) in the liver
tissue. RH-Glu was present in the perfusate and bile
only, and RH-110 was present in the perfusate and
liver tissue only. Neither IR-24 nor IR-72 had any
significant effect on the overall recovery of RH-123
(Figure 6A), RH-Glu (Figure 6B), or RH-110
(Figure 6C) or the total mass balance (Figure 6D).

The bile flow rates for individual intervals and
the average bile flow rates during the entire 60 min
perfusion of livers are presented in Figure 7.
Whereas the bile flow rates at the later intervals
were significantly (p<0.05) lower for the IR-24
group, relative to the values for the Sham-24 group
(Figure 7A), there was no difference in the flow
rates between the 72 h reperfusion groups (Figure
7B). In agreement with the individual interval data
(Figures 7A and B), the average flow rate for the
IR-24 group was 23% lower (p<0.05) than that in
the Sham-24 group (Figure 7C).
DISCUSSION
Recent reports (7, 8, 10) have shown that partial
liver IR injury significantly alters the gene
expression of Mrp2 and Mdr1b (P-gp) in the liver
of rats. Because these two transporters play a major
role in the biliary excretion of a number of drugs,
the pharmacokinetics of these drugs may be
significantly altered after the IR injury. In the
present study, we used an IPRL model to
investigate the effect of warm hepatic IR injury on
the hepatobiliary disposition of RH-123, which is a
dual marker of P-gp and Mrp2 function. Warm
hepatic IR injury significantly altered the
hepatobiliary disposition of RH-123, which is a Pgp marker, and its glucuronidated metabolite, which
is excreted into the bile by Mrp2 (Figures 3-5).
Both biliary excretion and biliary clearance (or
BEI) of RH-123 and RH-Glu were significantly
reduced after hepatic ischemia followed by 24 h of
reperfusion. However, both of these parameters
returned to normal levels after 72 h of reperfusion
(Figures 3-5). These data suggest substantial
decreases in the functional activity of both P-gp and
Mrp2 transporters 24 h following the IR injury.

Figure 6. The mass balance data for RH-123 (A), RHGlu (B), RH-110 (C), and total drug/metabolites (D) in
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The decrease in the biliary excretion (Figure 4) and
CLbile,app (Figure 5C) of the generated RH-Glu,
observed in our studies, is in agreement with the
reported (8-10, 23) downregulation of the mRNA
and protein levels of this transporter as a result of
hepatic IR injury.
In a partial IR model in rats identical to ours,
Tanaka et al. (8, 10) showed that the hepatic IR
injury caused a significant reduction in the Mrp2
mRNA in the liver tissue following 60 min of
ischemia and 24 h of reperfusion. However, the
mRNA levels returned to normal values after 48 h
of reperfusion. The decrease in the mRNA levels at
24 h (8, 10) was accompanied by 88 and 80%
reductions in the Mrp2 protein expression after 24
and 48 h of reperfusion, respectively (8). However,
the downregulation of the protein expression was
more extensive than that of mRNA, suggesting
additional post-transcriptional downregulation of
Mrp2 by IR (8). Our observation that the hepatic IR
decreases the CLbile,app of RH-Glu, a substrate of
Mrp2, by 83% after 24 h of reperfusion (Figure 5
C) is in close agreement with the findings of
Tanaka et al. Furthermore, our data suggest that this
effect is abolished 72 h following the reperfusion
(Figure 5C).
In addition to a reduced transport function for
Mrp2, our studies also revealed a substantial IRinduced reduction in the activity of P-gp, as
demonstrated by 92 and 50% reductions in the
CLbile,app (Figure 5A) and BEI (Figure 5B) of RH123, respectively. The reduction in the transport
activity of P-gp, however, does not correlate with
the limited data available on the effects of hepatic
IR on the Mdr1b mRNA (10) or P-gp protein
expression (7) reported before. Significant increases
(≥ 50%) in the Mdr1b mRNA was reported 6, 24,
and 48 h following reperfusion of rat livers (10).
Additionally, we are aware of one study (7) that
showed a modest (~20%), but statistically
significant, increase in the P-gp protein expression
in the liver of rats 12 h following reperfusion. The
lack of correlation between the P-gp expression and
functional activity, which has also been reported by
others (11, 24), may be due to several reasons. One
likely mechanism is that changes in the energy
status of the liver may be responsible for the
decreased activity of P-gp, an ATP binding cassette
transporter protein. Liver ATP concentrations,
which substantially decrease during the ischemic
period, gradually recover during the reperfusion of

Figure 7. The 10-min interval bile flow rates for the 24
(A) and 72 (B) h reperfusion groups and the average bile
flow rates during the entire 60 min of ex vivo perfusion
(C) in isolated livers. Livers were collected from rats
subjected to 1 h of partial hepatic ischemia (IR) or sham
operation (Sham), followed by 24 or 72 h of in vivo
reperfusion. The columns and bars represent the mean
and SD values, respectively. * p<0.05, significantly
different from the respective Sham group based on
repeated measure (A and B) or regular (C) two-way
ANOVA, followed by Bonferroni’s post-hoc analysis.
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the biliary excretion of the drug to its accumulation
in the liver (equation 4), instead of the perfusate, is
only a reflection of the efflux (from the liver to bile)
and not the uptake (from the perfusate to the liver)
of the drug. Indeed, the much higher magnitude of
reduction (92%) in CLbile,app (Figure 5A), compared
with the 50% reduction in BEI (Figure 5B), as a
results of IR-24, might have been due to additional
effects of IR-24 on the uptake of RH-123, which
could only be reflected in CLbile,app and not BEI.
Our suggestion that IR-24 decreases the
transport function of Mrp2 is based on the IRinduced reduction in the CLbile,app of RH-Glu
generated after the administration of RH-123.
Therefore, it may be argued that the biliary
excretion of RH-Glu might have been influenced by
potential changes in the formation of the metabolite
as a result of IR. However, the fact that the mass
balance data for the conjugated metabolite was not
affected by IR (Figure 6B) suggests that IR does not
affect the glucuronidation of RH-123. Nevertheless,
future studies using direct administration of Mrp2
substrates are needed to confirm the results
presented here using the formed metabolite RHGlu.
In addition to the no change in the extent of
glucuronidation of RH-123 (Figure 5B), mass
balance data also suggest that the hepatic IR injury
does not have any effect on the formation of RH110 in our model at 24 or 72 h after the reperfusion
(Figure 6C). Recently (18), we showed a significant
reduction in the cytochrome P450 reductase and
cytochrome P450 2E1-mediated metabolism of
chlorzoxazone 3 h following reperfusion of the
ischemic livers. However, the effect of IR on the
P450-mediated metabolism was absent at 24 h
following reperfusion. The lack of the effect of IR24 or IR-72 on the deacylation of RH-123 to RH110, observed here, is similar to the absence of the
effects of IR on cytochrome P450 reductase and
cytochrome
P450
2E1
metabolism
of
chlorzoxazone at 24 h following reperfusion.
In conclusion, warm hepatic IR injury reduces
the activities of both P-gp and Mrp2 in the rat liver
24 h after reperfusion of livers subjected to 60 min
of partial ischemia. However, the functions of these
transporters return to normal levels 72 h after
reperfusion. If extrapolated to humans, these
findings may have clinical ramifications for Mrp2
and P-gp substrate drugs that are administered
during the first 24 h after the ischemic insult to the

the liver (25, 26). Our attempts to accurately
measure the ATP concentrations in our IPRLs at the
end of the perfusion were unsuccessful because of
the extremely rapid and variable degradation of
ATP during the period between the end of perfusion
and preparation of the livers for the storage at
-80oC. However, using an IR model identical to
ours (60 min of partial ischemia in rats), Ofluoglu et
al. (27) reported that after 24 h of reperfusion, the
hepatic concentrations of ATP were ~30% lower
than that of sham-operated animals. Therefore, a
decrease in the liver ATP concentrations might
have superseded the modest increase reported (7) in
the protein levels of P-gp, explaining the lower Pgp activity observed in our IR-24 group.
Another possible reason for the apparent lack of
correlation between the P-gp protein and function
after hepatic IR may be related to the intracellular
trafficking of P-gp after the injury. The reported (7)
IR-induced increase in the P-gp expression was
based on Western blot analysis, which is a measure
of total tissue P-gp. However, it is possible that Pgp is retrieved from the bile canalicular membranes
into intrahepatic sites in the IR-24 livers. Indeed, it
has been reported (28, 29) that various factors, such
as the concentrations of cAMP, taurocholate, Ca++,
or ATP, which may potentially be altered after IR
injury, may affect the distribution of P-gp between
the canalicular membranes and intracellular sites at
the canalicular membrane.
It has been reported (30) that the uptake of RH123 in sandwich cultured rat hepatocytes consists of
both linear and saturable components, with Oatp1a4
as the likely carrier for the latter. Therefore, it may
be argued that an IR-induced decrease in the uptake
of RH-123 into the liver might have led to a
decrease in its biliary excretion. The possibility of
an IR effect on the influx transporters cannot be
ruled out based on our data. However, such an
effect, if indeed exists, cannot by itself explain our
biliary excretion data for RH-123 (Figures 5A and
B). Whereas a possible reduction in the uptake of
RH-123 may cause a reduction in CLbile,app (Figure
5A), it cannot explain the reduction observed in the
BEI value (Figure 5B). This is because CLbile,app is
estimated by dividing the rate (or amount) of the
drug excreted into the bile by its corresponding
perfusate concentration (or AUC). Therefore, a
reduction in the uptake, causing an increase in the
perfusate exposure to drug, will be reflected as a
reduction in CLbile,app. However, BEI, which relates

326

J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(2) 318 - 328, 2012

10. Tanaka Y, Chen C, Maher JM, Klaassen CD.
Kupffer cell-mediated downregulation of hepatic
transporter expression in rat hepatic ischemiareperfusion. Transplantation 2006; 82: 258-266.
11. Micuda S, Brcakova E, Fuksa L, Cermanova J,
Osterreicher J, Hroch M, Mokry J, Pejchal J,
Martinkova J, Staud F. P-glycoprotein function and
expression during obstructive cholestasis in rats.
Eur. J. Gastroenterol. Hepatol. 2008; 20: 404-412.
12. Parasrampuria R, Mehvar R. Hepatobiliary
disposition of rhodamine 123 in isolated perfused rat
livers. Xenobiotica 2008; 38: 1263-1273.
13. Parasrampuria R, Mehvar R. Effects of Pglycoprotein and Mrp2 inhibitors on the
hepatobiliary disposition of Rhodamine 123 and its
glucuronidated metabolite in isolated perfused rat
livers. J. Pharm. Sci. 2010; 99: 455-466.
14. Patel S, Pachter HL, Yee H, Schwartz JD, Marcus
SG, Shamamian P. Topical hepatic hypothermia
attenuates pulmonary injury after hepatic ischemia
and reperfusion. J. Am. Coll. Surg. 2000; 191: 650656.
15. Weinbroum AA, Hochhauser E, Rudick V, Kluger
Y, Sorkine P, Karchevsky E, Graf E, Boher P,
Flaishon R, Fjodorov D, Niv D, Vidne BA. Direct
induction of acute lung and myocardial dysfunction
by liver ischemia and reperfusion. J Trauma 1997;
43: 627-633; discussion 633-625.
16. Lee HT, Park SW, Kim M, D'Agati VD. Acute
kidney injury after hepatic ischemia and reperfusion
injury in mice. Lab. Invest. 2009; 89: 196-208.
17. Behrends M, Hirose R, Park YH, Tan V, Dang K,
Xu F, Park SH, Niemann CU. Remote renal injury
following partial hepatic ischemia/reperfusion injury
in rats. J. Gastrointest. Surg. 2008; 12: 490-495.
18. Shaik IH, Mehvar R. Effects of normothermic
hepatic ischemia-reperfusion injury on the in vivo,
isolated perfused liver, and microsomal disposition
of chlorzoxazone, a cytochrome P450 2E1 probe, in
rats. J. Pharm. Sci. 2011; 100: 5281-5292.
19. Shaik IH, Mehvar R. Cytochrome P450 induction by
phenobarbital exacerbates warm hepatic ischemiareperfusion injury in rat livers. Free Radic. Res.
2010; 44: 441-453.
20. Mehvar R, Zhang XP. Development and application
of an isolated perfused rat liver model to study the
stimulation and inhibition of tumor necrosis factoralpha production ex vivo. Pharm. Res. 2002; 19:
47-53.
21. Mehvar R, Chimalakonda AP. Hepatic disposition of
cyclosporine A in isolated perfused rat livers. J.
Pharm. Pharm. Sci. 2004; 7: 47-54.
22. Liu X, Chism JP, LeCluyse EL, Brouwer KR,
Brouwer KL. Correlation of biliary excretion in
sandwich-cultured rat hepatocytes and in vivo in
rats. Drug Metab. Dispos. 1999; 27: 637-644.

liver. Further studies, including in vivo and
mechanistic experiments, are needed to determine
the effects of liver IR injury on the extent of
alterations in the overall pharmacokinetics and
pharmacodynamics of drugs whose elimination is
dependent on their excretion into the bile.
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